JoVE Logo
Faculty Resource Center

Sign In

Summary

Abstract

Introduction

Protocol

Representative Results

Discussion

Acknowledgements

Materials

References

Medicine

Endotoxin Activity Assay for the Detection of Whole Blood Endotoxemia in Critically Ill Patients

Published: June 24th, 2019

DOI:

10.3791/58507

1Department of Anesthesia and Critical Care, Niguarda Hospital, 2University of Milan-Bicocca Medical School

We hereby present a protocol to measure at the bedside the endotoxin activity of human whole blood samples. The Endotoxin Activity assay is a simple test to perform and may be a useful biomarker in critically ill patients with sepsis.

Lipopolysaccharide, also known as endotoxin, is a fundamental component of gram-negative bacteria and plays a crucial role in the development of sepsis and septic shock. The early identification of an infectious process that is rapidly evolving to a critical illness might prompt a quicker and more intensive treatment, thereby potentially leading to better patient outcomes. The Endotoxin Activity (EA) assay can be used at the bedside as a reliable biomarker of systemic endotoxemia. The detection of elevated endotoxin activity levels has been repeatedly shown to be associated with an increased disease severity in patients with sepsis and septic shock. The assay is quick and easy to perform. Briefly, after sampling, an aliquot of whole blood is mixed with an anti-endotoxin antibody and with added LPS. Endotoxin activity is measured as the relative oxidative burst of primed neutrophils as detected by chemioluminescence. The assay's output is expressed on a scale from 0 (absent) to 1 (maximal) and categorized as “low” (<0.4 units), “intermediate” (0.4–0.59 units), or “high” (≥0.6 units). The detailed methodology and rationale for the implementation of the EA assay are reported in this manuscript.

The Lipopolysaccharide (LPS), also known as endotoxin, is a key component of the membrane structure of Gram-negative (GN) bacteria. It makes up about 10% of the cell wall, being vital for the outer membrane integrity and homeostasis. Moreover, it is a potent activator of the host innate immune system1,2.

In vitro exposure of innate immune system cells to LPS leads to changes in the expression of multiple genes3. Administration of very small quantities of LPS in healthy human volunteers triggers the cascade of acute systemic inflammation, whereas sepsis and se....

Log in or to access full content. Learn more about your institution’s access to JoVE content here

The protocol is conducted according to institutional guidelines relating to the handling of human biospecimens and following the current standard operative procedures of our clinical laboratory. The use of EA data and clinical information of patients being tested follows the guidelines of our institution’s human research ethics committee.

1. Laboratory Equipment and Assay Kit Contents

  1. Store the EA kit at 2–8 °C when not in use.
  2. Each EA test consis.......

Log in or to access full content. Learn more about your institution’s access to JoVE content here

A 72 year-old man was admitted to the Emergency Department (ED) of an academic urban hospital. A few days earlier he had presented to his primary care physician complaining of burning on urination. A short-course therapy with oral phosphomycin was recommended. His medical history included hypertension, uncomplicated type-2 diabetes and benign prostatic hyperplasia. His medications included enalapril, atorvastatin, tamsulosin and metformin.

Log in or to access full content. Learn more about your institution’s access to JoVE content here

Septic shock is still nowadays associated with a mortality as high as 40%, although this rate varies according to the considered reports16. The need for novel and better biomarkers is advocated by most experts in the fields in order to aid clinicians in early diagnosis, better management, and prognostication of patients with septic shock6.

Performing an EA test does not require previous technical knowledge or sophisticated laboratory equipment, a.......

Log in or to access full content. Learn more about your institution’s access to JoVE content here

We thank Paolo Braganò and Lisa Mathiasen, Ph.D. for their review of the assay protocol methodology. Dario Winterton, MD provided substantial help reviewing the manuscript for English language proficiency.

....

Log in or to access full content. Learn more about your institution’s access to JoVE content here

Name Company Catalog Number Comments
EAA kit Spectral Medical Inc. EAAST-20 Package with 20 tests + 1 quality control
Smart Line TL Berthold EAASL Luminometer
Incubator shaker GRANT ES-20 Mini-incubator shaker
Vortexer VWR 444-2790 Vortex instrument

  1. Akira, S., Takeda, K. Toll-like receptor signalling. Nature Reviews Immunology. 4 (7), 499-511 (2004).
  2. Takeda, K. Evolution and integration of innate immune recognition systems: the Toll-like receptors. Journal of Endotoxin Research. 11 (1), 51-55 (2005).
  3. Ulevitch, R. J., Tobias, P. S. Recognition of gram-negative bacteria and endotoxin by the innate immune system. Current Opinion in Immunology. 11 (1), 19-22 (1999).
  4. Natanson, C., et al. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. The Journal of Experimental Medicine. 169 (3), 823-832 (1989).
  5. Suffredini, A. F., et al. The cardiovascular response of normal humans to the administration of endotoxin. The New England Journal of Medicine. 321 (5), 280-287 (1989).
  6. Singer, M., et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA: The Journal of the American Medical Association. 315 (8), 801-810 (2016).
  7. Gupta, S., et al. Culture-Negative Severe Sepsis: Nationwide Trends and Outcomes. Chest. 150 (6), 1251-1259 (2016).
  8. Ikeda, T., Ikeda, K., Suda, S., Ueno, T. Usefulness of the endotoxin activity assay as a biomarker to assess the severity of endotoxemia in critically ill patients. Innate Immunity. 20 (8), 881-887 (2014).
  9. Dellinger, R. P., et al. Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level. The EUPHRATES Randomized Clinical Trial. JAMA: The Journal of the American Medical Association. 320 (14), 1455-1463 (2018).
  10. Marshall, J. C., et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. The Journal of Infectious Diseases. 190 (3), 527-534 (2004).
  11. Levin, J., Bang, F. B. Clottable protein in Limulus; its localization and kinetics of its coagulation by endotoxin. Thrombosis et Diathesis Haemorrhagica. 19 (1), 186-197 (1968).
  12. Marshall, J. C., et al. Measurement of endotoxin activity in critically ill patients using whole blood neutrophil dependent chemiluminescence. Critical Care. 6 (4), 342-348 (2002).
  13. Grimaldi, D., et al. High Level of Endotoxemia Following Out-of-Hospital Cardiac Arrest Is Associated With Severity and Duration of Postcardiac Arrest Shock. Critical Care Medicine. 43 (12), 2597-2604 (2015).
  14. Klein, D. J., et al. The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial. Trials. 15, 218 (2014).
  15. Bottiroli, M., et al. Prevalence and clinical significance of early high Endotoxin Activity in septic shock: An observational study. Journal of Critical Care. 41, 124-129 (2017).
  16. Kaukonen, K. M., Bailey, M., Suzuki, S., Pilcher, D., Bellomo, R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand. JAMA: The Journal of the American Medical Association. 311 (13), 1308-1316 (2014).
  17. Biagioni, E., et al. Endotoxin activity levels as a prediction tool for risk of deterioration in patients with sepsis not admitted to the intensive care unit: a pilot observational study. Journal of Critical Care. 28 (5), 612-617 (2013).
  18. Roth, R. I., Levin, F. C., Levin, J. Optimization of detection of bacterial endotoxin in plasma with the Limulus test. The Journal of Laboratory and Clinical Medicine. 116 (2), 153-161 (1990).
  19. Yaguchi, A., Yuzawa, J., Klein, D. J., Takeda, M., Harada, T. Combining intermediate levels of the Endotoxin Activity Assay (EA) with other biomarkers in the assessment of patients with sepsis: results of an observational study. Critical Care. 16 (3), (2012).
  20. Earley, Z. M., et al. Burn Injury Alters the Intestinal Microbiome and Increases Gut Permeability and Bacterial Translocation. PLoS One. 10 (7), (2015).
  21. Munster, A. M., Smith-Meek, M., Dickerson, C., Translocation Winchurch, R. A. Incidental phenomenon or true pathology?. Annals of Surgery. 218 (3), 321 (1993).
  22. Clementi, A., Virzì, G. M., Brocca, A., Ronco, C. The Role of Endotoxin in the Setting of Cardiorenal Syndrome Type 5. Cardiorenal Medicine. 7 (4), 276-283 (2017).
  23. Virzì, G. M., et al. Cardiorenal Syndrome Type 5 in Sepsis: Role of Endotoxin. in Cell Death Pathways and Inflammation. Kidney and Blood Pressure Research. 41 (6), 1008-1015 (2016).
  24. Mignon, F., Piagnerelli, M., Van Nuffelen, M., Vincent, J. L. Effect of empiric antibiotic treatment on plasma endotoxin activity in septic patients. Infection. 42 (3), 521-528 (2014).
  25. Klein, D. J., et al. Daily variation in endotoxin levels is associated with increased organ failure in critically ill patients. Shock. 28 (5), 524-529 (2007).

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved